Codagenix, 238 Main St, Cambridge, MA 02142, US

Ankyra Therapeutics Inc, based in Cambridge, MA, is a clinical-stage biotech company specializing in developing anchored-drug conjugates for triggering long-lasting anti-tumor responses while ensuring safety. By leveraging their expertise in drug development, the company aims to optimize anchored immunotherapy to enhance the lives of cancer patients. Their unique approach involves designing products with enhanced tumor retention, believing that prolonged drug presence in tumors leads to more significant clinical benefits. These anchored-drug conjugates are meticulously crafted to bind molecules to aluminum hydroxide, thereby extending anti-tumor immune activation, reducing systemic side effects, and requiring less frequent dosing for efficacy. Through their Anchored Immunotherapy platform, Ankyra Therapeutics focuses on creating anchored molecules to improve the safety profiles of drugs that face challenges due to dose-limiting toxicities. Their pipeline includes the promising ANK-101, an IL-12 anchored-drug conjugate exhibiting potent therapeutic activity in preclinical models and now undergoing evaluation in patients with advanced solid tumors. Generated from the website content

Veritas Medicine

Noodle Lab

Technology Enabling Corp

The Consensus Building Institute Inc